Investor Presentaiton

IBI-188 (Letaplimab, CD47 mAb) Development Plan Overview Potential Best-in-class anti-CD47 antibody with Fast Development Progress IBI-188 Differentiated Advantages Optimized affinity for balanced toxicity and efficacy Stronger efficacy than hu5F9 and comparable tolerability in NHPS Tumor volume (mm³) 1750 1500- 1250- 1000- 750- 500- Pre-clinical Highlights IBI188 in Raji on NOD/SCID model 250- 0 8 11 13 16 20 23 27 30 34 Days post tumor implantation Clinical Highlights Phase 1a data published on SITC 2020: Well tolerated. Completed all pre-specified seven dosage without any DLT (maximum dose 30mg/kg QW). Good safety profile. TRAE mostly grade 1-2. 15% Anemia at controllable level. Anti-tumor activity observed in 1a. IBI-188 Development Program Overview Clinical vehicle progress h-IgG, 0.5 mg/kg IBI188, 0.02mg/kg IBI188, 0.1mg/kg IBI188, 0.5mg/kg • AML MDS Keep enrolling patients for the Phase 1b study for r/r AML Keep enrolling patients for the Phase 1b study for 1L MDS AML Complete patient enrolment for the Phase 1b study for r/r AML 2021 plan • MDS Complete patient enrolment for the Phase 1b study for 1L MDS Good tolerability and safety profile in 63 patients dosed in Phase 1a. Proven efficacy in ongoing Phase 1b studies for AML and MDS. Global development ongoing; China to complete patient enrolment Phase 1b studies in 2021. Innovent Confidential Copyright©2021 Innovent Biologics 28

View entire presentation